title: Combined treatment in Wegener's granulomatosis with crescentic glomerulonephritis--clinical course and long-term outcome.
abstract: This study reports on 9 patients suffering from Wegener's granulomatosis (WG) with crescentic GN and severe systemic manifestations. On admission the mean serum creatinine was 10.9 +/- 5.1 mg/dl (4-20 mg/dl); 8 patients were oliguric and required dialysis treatment. Renal biopsy showed crescents in all cases, involving 66 to 100% of glomeruli. Patients were treated with a protocol including: a plasma exchange (PE) course; methylprednisolone; cyclophosphamide; and an antithrombotic agent (defibrotide). Clinical picture and renal function progressively improved in all patients within the first 4 weeks of treatment. After 1 month serum creatinine was 2.7 +/- 0.8 mg/dl and dialysis was no longer needed in any patient. Five relapses occurred in 3 patients 12-26 months after the onset of the disease, while they were still receiving immunosuppressive treatment. At follow-up (22 to 112 months: mean 71) all patients were alive with no clinical signs of disease activity. One patient was on regular dialysis while the others had a serum creatinine of 1.2-2.8 mg/dl (mean 1.9). Our results confirm that crescentic GN associated with WG can be successfully treated even when associated with severe clinical picture and suggest that PE can contribute to control the disease without increasing immunosuppression.
authors.affiliation: Institute of Nephrology, St. Orsola University Hospital, Bologna, Italy.
authors.forename: G M
authors.initials: GM
authors.lastname: Frascà
authors.forename: N G
authors.initials: NG
authors.lastname: Zoumparidis
authors.forename: L C
authors.initials: LC
authors.lastname: Borgnino
authors.forename: L
authors.initials: L
authors.lastname: Neri
authors.forename: L
authors.initials: L
authors.lastname: Neri
authors.forename: A
authors.initials: A
authors.lastname: Vangelista
authors.forename: V
authors.initials: V
authors.lastname: Bonomini
mesh_terms: D000328:Adult; D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies / Q000032:analysis; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007668:Kidney / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D010951:Plasma Exchange; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D001323:Autoantibodies; D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; C036901:defibrotide; D003520:Cyclophosphamide; D008775:Methylprednisolone